Tarsus Pharmaceuticals Inc (TARS) posted record Q3 2026 Xtendi net product sales of $194.6 million, up nearly 64% year over year, and lifted its full-year 2026 guidance to $715-$730 million.
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus Pharmaceuticals may be undervalued after its pullback, with Xdemvy growth, pipeline upside, and key catalysts ahead. Read the full analysis here on TARS stock.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.
Elizabeth Yeu Lin, Chief Medical Officer, on September 04, 2026, sold 13,953 shares in Tarsus Pharma
Seshadri Neervannan, Chief Operating Officer, on September 04, 2026, sold 4,564 shares in Tarsus Pha
Tarsus Pharmaceuticals (TARS) said Friday that it has completed its acquisition of retinal disease-f
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend ...
This is the newest page. Registered accounts read further back.